Lebrikizumab - Wikipedia
Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). [ 7 ] [ 8 ] It is an interleukin-13 antagonist. [ 7 ] It is given by subcutaneous injection .
礼来IL-13抗体疗法lebrikizumab在中国获批临床，治疗特应性皮炎
2023年12月19日 · Lebrikizumab 是一种新型的抗 IL-13 单克隆抗体，具有生物利用度高和半衰期长的特点，能够高亲和力结合可溶性 IL-13 ，阻断 IL-13 介导的信号通路。 此前， Lebrikizumab 曾获得 FDA 的快速通道资格。
Lebrikizumab Uses, Side Effects & Warnings - Drugs.com
2024年10月14日 · What is lebrikizumab? Lebrikizumab is used alone or with topical medications (for the skin) to treat moderate-to-severe eczema (atopic dermatitis) in adults and children at least 12 years old that weigh at least 88 pounds (40 kg). Lebrikizumab is used when other topical treatments did not work or stopped working.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe …
2023年3月15日 · Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor signaling complex.
来金珠单抗(Lebrikizumab) - 药物靶点：IL-13_在研适应症：特应 …
2018 年，Simpson 等人发表了一项随机、安慰剂对照、双盲研究在 18 岁及以上的成人中度至重度患者中进行比较的研究AD 使用局部皮质类固醇，2022 年，Silverberg 等人进行了两项随机、双盲、评估 Lebrikizumab 的安慰剂对照III 期试验。
全球首批！湿疹创新疗法让过半患者症状减轻75%以上
2023年11月18日 · Lebrikizumab是一种单克隆抗体，能高亲和力结合IL-13，有效阻止IL-13Rα1/IL-4Rα异二聚体复合物的形成及其后续信号传导 。这种抑制显著减轻了IL-13的生物 ...
Ebglyss (lebrikizumab-lbkz,来瑞组单抗)治疗特应性皮炎中文说明 …
2024年10月11日 · Lebrikizumab-lbkz是一种白细胞介素-13拮抗剂，是一种免疫球蛋白G4 (IgG4)单克隆抗体，可结合白细胞介素(IL)-13并抑制IL-13信号传导。 Lebrikizumab-lbkz通过重组DNA技术在中国仓鼠卵巢(CHO)细胞中产生。
特应性皮炎 (AD)新药！礼来IL-13抑制剂lebrikizumab联合治疗关键3期研究成功：清除皮损、改善瘙痒!
lebrikizumab是一种新型单克隆抗体（mAb），能够以高亲和力结合可溶性IL-13，具有高生物利用度、长半衰期，可阻断IL-13信号转导。
Lebrikizumab (Ebglyss) - NCBI Bookshelf
Lebrikizumab is available as a 250 mg per 2 mL solution in a prefilled pen or prefilled syringe with needle shield for subcutaneous (SC) injection. The recommended initial dose is 500 mg (two 250 mg injections) at week 0 and week 2, followed by 250 mg (1 injection) every 2 weeks until week 16. Once clinical response is achieved, the recommended ...
Lebrikizumab: Efficacy, Safety, and More - DermNet
What is lebrikizumab? Lebrikizumab is a novel, high-affinity, monoclonal antibody or biological agent that selectively inhibits interleukin 13 (IL-13) for the treatment of atopic dermatitis (eczema). The US Food and Drug Administration (FDA) granted lebrikizumab Fast Track designation for atopic dermatitis (AD) in Dec 2019.